Educational resources are an essential component of the mission of PCSK9 Forum to increase awareness and understanding of PCSK9 science and therapeutics.

PCSK9 Forum has recently launched a series of educational slide decks analysing key results from important trials in the PCSK9 field.

The third slide decks in this series probe further into the FOURIER study and the ODYSSEY clinical trial programme. The latest FOURIER slide deck overviews an analysis of the efficacy of evolocumab according to the severity and extent of coronary artery disease. The ODYSSEY slide deck focuses on the ODYSSEY-DM Insulin trial, the first study with a PCSK9 inhibitor that specifically randomised individuals with insulin‐treated diabetes not at LDL cholesterol goal, despite maximally-tolerated statin therapy. These slide decks capture all the essentials from these analyses with expert interpretation for clinicians involved in the management of high- and very high-risk patients.

Bookmark this page for the next in this programme.